circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

• Главные авторы: Yutang Huang (Автор), Yi Dai (Автор), Chunjie Wen (Автор), Shuai He (Автор), Jingjing Shi (Автор), Dezhang Zhao (Автор), Lanxiang Wu (Автор), Honghao Zhou (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2020-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated. Recent studies have indicated that circular RNAs play a crucial role in chemoresi...